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ABSTRACT In branch retinal vein occlusion (BRVO), abnormal arteriovenous
crossing with vein compression, degenerative changes of the vessel wall and
abnormal hematological factors constitute the primary mechanism of vessel oc-
clusion. In general, BRVO has a good prognosis: 50–60% of eyes are reported
to have a ﬁnal visual acuity (VA) of 20/40 or better even without treatment.
One important prognostic factor for ﬁnal VA appears to be the initial VA. Grid
laser photocoagulation is an established treatment for macular edema in a par-
ticular group of patients with BRVO, while promising results for this condition
are shown by intravitreal application of steroids or new vascular endothelial
growth factor inhibitors. Vitrectomy with or without arteriovenous sheatho-
tomy combined with removal of the internal limiting membrane may improve
vision in eyes with macular edema which are unresponsive to or ineligible for
laser treatment.
KEYWORDS branch retinal vein occlusion; pathogenesis; risk factors; treatment; visual
prognosis
BACKGROUND
Method of Literature Search
Eligible studies were identiﬁed through a comprehensive literature search of
electronic databases (Medline, 1966–September 2007 and Science Direct, all
years). Additional articles were selected from review of the reference lists of the
articles generated from the above search. The following keywords and combi-
nations of these words were used in compiling the search: branch retinal vein
occlusion, retinal circulatory disorders, pathogenesis, hematological disorders,
risk factors, therapy methods, visual prognosis. In total, 150 of these were used
for this mini-review.
Epidemiology, Classiﬁcation
Retinal vein occlusion (RVO) is the second most common retinal vascular
disorder after diabetic retinopathy and is a signiﬁcant cause of visual handicap.
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111Its prevalence has been shown to vary from 0.7% to
1.6%.1,2 In a population-based study,3 an overall in-
cidence of symptomatic RVO was found in 0.21% of
patientsaged40orolder.Hayrehetal.4 investigatedthe
demographic characteristics of various types of RVO in
1108 patients (1229 eyes). In this study, a male:female
ratio of 1.2:1 was noted in a group of patients with
RVO. Of the two main types of RVO, central retinal
vein occlusion (CRVO) and branch retinal vein occlu-
sion (BRVO), the latter is more common. A further
group is hemi-vein occlusion, a distinct clinical entity
presenting as occlusion of only one trunk of the central
retinal vein in the area of the anterior part of the optic
nerve.4 Hayreh et al.4 postulated that its pathogenesis
is closely related to CRVO.
The ﬁrst case of BRVO was reported by Leber in
1877.5 Some studies showed a higher proportion of
BRVO patients older than 65 at the onset of the
disease compared to CRVO,4,6 but others found no
signiﬁcance of age in the distribution of CRVO and
BRVO.7,8 BRVO is divided into two distinct entities:
major BRVO, when one of the major branch retinal
veins is occluded, and macular BRVO, when one of
the macular venules is occluded. In 66% of eyes with
BRVO, there is occlusion of the major branch in the
superotemporal quadrant followed by 22–43% of eyes
with occlusion of the major branch in the inferotem-
poral quadrant.9 Owing to absent subjective BRVO
symptoms in nasal quadrants, the diagnosis of occlu-
sion in this localization is mostly accidental and there-
fore rare.10 Very often BRVO in nasal quadrants is di-
agnosed only when its complication as bleeding from
neovascularizations into the vitreous cavity occurs. The
cumulative probability of developing a second episode
of occlusion in the other eye within 4 years is about 7%
in patients with BRVO.4
Pathogenesis
The pathogenesis of RVO is multifactorial while
BRVO may be due to a combination of three primary
mechanisms: compression of the vein at the arteriove-
nous (A/V) crossing, degenerative changes of the vessel
wall, and abnormal hematological factors. In the fol-
lowing sections these factors are discussed.
Arteriovenous Crossing
Koyanagi in 192811 ﬁrst reported the association be-
tween BRVO and A/V crossing, and now it is estab-
lished that mechanical narrowing of the venous lumen
at these intersections plays a role in the pathogenesis
of BRVO. Anatomic features of A/V crossings and sec-
ondary effects of arteriolar sclerosis may explain the ap-
parentvulnerabilityofthecrossingsitetovenousocclu-
sion. In the majority of A/V crossings, the thin-walled
vein lies between the more rigid thick-walled artery and
the highly cellular retina. The sharing by artery and
vein of the common adventitial sheath and the narrow-
ing of the venous lumen that normally occurs at the
A/V crossing provide the setting for BRVO.12 The risk
of occlusion may be accentuated when arteriolar scle-
rosis results in increased rigidity of the crossing artery.
Duker and Brown13 provided further support for a me-
chanical basis of BRVO development when they ex-
amined the relative anatomic position of the crossing
artery and vein at the site of occlusion in 26 eyes with
BRVO. They found in all 26 eyes the artery anterior
to the vein (towards the vitreous cavity). Zhao et al.12
evaluated the anatomic position of the crossing vessels
in 106 eyes with BRVO and found the artery anterior
to the vein at the obstructed site in 99% of affected
eyes. However, other mentioned risk factors must play
a role, too, because in approximately 60% of normal
A/V crossings without BRVO the artery lies anterior to
vein.12
Degenerative Changes of Vessel Wall
A number of studies have investigated the histolog-
ical changes of vessel wall at the A/V crossing.14,15 An
investigation by Jefferies et al.14 showed that the ex-
pected venous compression at the crossing in histologi-
cal view does not exist. He described the bending of the
vein into the nerve ﬁber layer at this point without its
compression. Histological investigation of the venous
lumen at the A/V crossing in patients with a number of
months to several years duration of BRVO showed or-
ganized thrombus with varied extent of recanalization
in this part. Seitz15 described the clinical histological
correlation in one eye with BRVO of a few hours after
onset. There was no blood thrombus obliterating the
venous lumen at the A/V crossing and even the fun-
doscopic examination showed strong dilated and tortu-
ous vein distal to the crossing. In the area of the A/V
crossing, alteration of the endothelium and intima me-
dia was present. Seitz suggests that the trophic changes
of venous endothelium and intima media, as they fol-
low the compression from overlaying artery, is the root
of the pathogenesis of BRVO.15 The formation of the
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of Frangieh et al.16 support this hypothesis; 90% of the
patients in their study had evidence of intima media
layer hypertrophy, and all had evidence of intravenous
thrombosis.
Systemic hypertension, diabetes mellitus, atheroscle-
rosis, and smoking are reported to be more common in
patients with RVO.1,2,10 Sclerosis of the retinal artery
which is associated with these systemic disorders may
result in further compression of the vein, when the
increased rigidity of arterial wall and contraction of
the adventitial sheath shared by artery and vein oc-
cur. Mechanical obstruction of the vein through the
rigid artery in the A/V crossing may result in turbu-
lent blood ﬂow producing damage to venous endothe-
lium and intima media and the sequence of events lead-
ing to occlusion of the vein.12,14 The turbulent blood
ﬂow was conﬁrmed by Christoffersen and Larsen in an
investigation which analyzed the ﬂuorescein an-
giograms of 250 patients with BRVO.17
Hematological Disorders
Some studies have revealed an association between
BRVO and hyperviscosity due to high hemotocrit.18,19
Higher blood viscosity increases under conditions of
low blood ﬂow and erythrocyte aggregation.18 Vis-
cosity is mainly dependent upon the hematocrit (the
greater the number of erythrocytes, the larger they ag-
gregate) and plasma ﬁbrinogen (required for aggrega-
tion to occur).20 Another discussed hematological dis-
order in the pathogenesis of BRVO is dysregulation of
the thrombosis-ﬁbrinolysis balance.21 The coagulation
cascade including different blood factors results in the
production of thrombin which converts circulating ﬁb-
rinogen to ﬁbrin. The coagulation sequence is held in
check and inhibited by speciﬁc anticoagulants includ-
ing protein C, protein S, and antithrombin. Table 1
showsthemajordisordersstudiedinpatientswithRVO.
The results of published studies, however, are inconsis-
TABLE 1 Most discussed coagulation and anticoagulation dis-
orders in the etiology of BRVO
• Resistance to activated protein C (especially factor V
Leiden mutation)
• Protein C or protein S deﬁciency
• Deﬁciency of antithrombin III
• Genetic mutation in the prothrombin (factor II) gene
• Anti-phospholipid antibodies
• Hyperhomocysteinemia
tent, and the role of coagulation factors in the develop-
ment of RVO remains unclear.
Resistance to Activated Protein C and
Deﬁciency of Protein C or Protein S
ProteinCisserineproteinasewhoseactivatedformis
a potent inhibitor of coagulation factors V and VIII.22
Factors V and VIII are a part of the coagulation cascade
leading to conversion of ﬁbrinogen to ﬁbrin. Patients
with protein C deﬁciency frequently manifest superﬁ-
cial and deep venous thrombosis and pulmonary em-
bolism. Protein S and phospholipids are co-factors in
the inactivation of factors V and VIII by activated pro-
tein C.22 An absolute deﬁciency of protein C or S is
relatively rare. Tekeli23 and several other authors have
reported normal levels in patients with RVO.24−26 The
concept of resistance to activated protein C (so-called
APC resistance) was ﬁrst introduced by Dahlb¨ ack et al.
in 1993.27 APC resistance was subsequently shown to
be a risk factor for venous thrombosis.28 More than
90% of patients with APC resistance have been shown
to have a single point mutation in factor V gene.29 This
mutation hinders the degradation of factor V normally
occurring through protein C. Several investigators have
reported an increased frequency of APC resistance in a
cohort of patients with RVO,30−34 but this association
hasnotbeenconﬁrmedinotherstudies.35,36 Moreover,
some results are inconclusive due to small patient sam-
ples or the lack of control groups. The meta-analysis
of Janssen et al.21 showed the odds ratios for factor V
LeidenmutationinpatientswithRVO1.5(95%CI0.8–
3.2). Despite the evidence of the signiﬁcance of Leiden
mutation, the effect of this hematological disorder in
the etiology of RVO is only marginal.21
Deﬁciency of Antithrombin and
Mutation in the Prothrombin Gene
InrecentstudiesofpatientswithRVO,nosigniﬁcant
association with a deﬁciency of antithrombin or with
prothrombin mutation was found.21,26,34,37−40
Anti-Phospholipid Antibodies and
Hyperhomocysteinemia
Antiphospholipid antibodies (APA) consist of a het-
erogeneous group of immunoglobulins, mainly anti-
cardiolipin antibodies (ACA) and lupus anticoagulants
(LA). Circulating APA leads to a hypercoagulable state
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tion and inhibition of the natural anticoagulant path-
ways by binding of membrane phospholipids. Both the
presence of LA and increased level of ACA are asso-
ciated with a 3- to 10-fold increased risk of venous
thrombosis.41
An elevated level of the amino acid, homocysteine
is now generally accepted to be a risk factor for sys-
temicvasculardisease.42 Homocysteineappearstohave
a deleterious effect on vascular endothelium and may
induce increased platelet aggregation and thrombosis.
Levels of homocysteine may be increased by dietary
habits, prescription medicines, or enzymatic mutations
affecting homocysteine metabolism.43 The results of
meta-analyses conﬁrm total homocysteine to be an in-
dependentriskfactorforRVO.21,44 Loewensteinetal.45
investigated the prevalence of genetic mutation in the
enzyme methylentetrahydrofolate reductase (MTHFR)
whose impaired activity may lead to hyperhomocys-
teinemia. The prevalence of this mutation was signiﬁ-
cantly higher in patients with RVO compared with the
incidence of MTHFR in a control population. How-
ever,theseresultswerenotconﬁrmedinotherstudies.46
The meta-analysis of Cahill et al.44 showed an associ-
ation between retinal vascular occlusion and hyperho-
mocysteinemia but not with the mutation in the gene
for MTHFR.
Pathogenesis of Macular Edema in BRVO
The development of macular edema (ME) followed
by BRVO has been hypothesized to be caused by
ﬂuid ﬂux from vessels to tissue according to Starling’s
law,47,48 which is based on the breakdown of the blood-
retinal barrier (BRB) as a result of damage to the tight
junctions of capillary endothelial cells,49 vitreoretinal
adhesion,50 and secretion into the vitreous of vasop-
ermeability factors produced in the retina.51,52 Ob-
servations by Noma et al.52 suggest that in patients
with BRVO, vascular occlusion induces the expres-
sion of vascular endothelial growth factor (VEGF) and
Interleukin-6 (IL-6), resulting in BRB breakdown and
increased vascular permeability. Thus, VEGF and IL-6
may contribute to the development and progression of
vasogenic ME in BRVO. ME is closely associated with
retinal hypoxia, and the degree of hypoxia in the center
of the macula corresponds to the decrease in visual acu-
ity (VA). If marked hypoxia persists, irreversible struc-
turalchangesinthemaculaoccur,andthedisturbedVA
is almost always lasting. It is generally known that ME
and intraretinal hemorrhage occurring in BRVO usu-
ally disappear within 6 to 12 months.53 In these cases,
collateral systems often develop. The main purpose of
the treatment is to decrease the duration of edema to
prevent photoreceptor damage, if no spontaneous im-
provement occurs.
Clinical Signs and Diagnosis
In general, diagnosis of BRVO is not a problem ow-
ing to its classical features. Major BRVO can be asymp-
tomatic or with visual blurring usually involving the
sector of visual ﬁeld corresponding to the area of the
retina involved. In macular BRVO, there is always a
central visual disturbance with normal peripheral vi-
sion. Acute BRVO presents characteristic clinical fea-
tures with ﬂame-shaped, dot and blot hemorrhage, soft
and hard exudates, retinal edema, and dilated, tortuous
vein in a segmental distribution. Signs of old occlusion
are vascular sheathing and venous collaterals. The diag-
nosis is based on clinical examination under slit lamp
and fundoscopy in artiﬁcial mydriasis. VA is of great
importance for future visual prognosis. BRVO often
leads to retinal non-perfusion zones in the occlusion
area. Fluorescein angiography is particularly useful in
determining the extent of ME and ischemia, although
the ischemic areas are often obscured by the presence
of intraretinal hemorrhage. Retinal neovascularization
occurs in 36% of eyes with an area of non-perfusion
greater than 5 disc diameter.54
RVO is associated with an increase in vascular causes
of death (both cerebral and cardiac) in large prospec-
tive follow-up studies.55 In all patients with RVO, the
systemic risk factors (hypertension, diabetes mellitus,
blood lipid disorders) should be investigated and man-
aged by appropriate specialists.
Natural Course and Visual Prognosis
The visual outcome following the natural course of
BRVO is well documented.56−58 In general, BRVO has
a good prognosis: 50–60% of eyes have been reported
to have a ﬁnal VA of 20/40 or better even without
any treatment.56−59 The natural course of BRVO is de-
termined by the site and degree of occlusion, the in-
tegrity of arterial perfusion to the affected sector, and
the efﬁciency of the developing collateral circulation.59
Chronic ME and bleeding into the vitreous from neo-
vascularizations account most frequently for a poor ﬁ-
nalVA.54,58,60 Retinalneovascularizationandpersistent
J. Rehak and M. Rehak 114TABLE 2 Final visual acuity of 20/200 or worse in relation to ini-
tial visual acuity. Chi-squared test with Yates correction (p < 0.05)
Initial visual Initial visual
acuity 20/50 acuity 20/200 Chi-squared
or better or worse test p< 0.05
Natural course—without laser treatment
Gutman56 5% (1/20) 50% (6/12) Signiﬁcant
Magargal58 0% (0/35) 83% (24/29) Signiﬁcant
Had undergone laser treatment
Wetzig53 25% (2/8) 67% (10/15) No
Jalkh64 0% (0/9) 33% (3/12) No
Magargal58 13% (5/40) 50% (32/64) Signiﬁcant
Lang66 8% (1/13) 50% (8/16) Signiﬁcant
ME develop in 25% and 60% of eyes, respectively.57,61
Gutman et al.60 found that in the natural course of
BRVO, only 14% of eyes with chronic ME retained a
VA of 20/40 or better, while 86% had a ﬁnal VA of
20/50 or worse. He concluded that chronic ME has a
poor prognosis in terms of ﬁnal VA.60 Schilling et al.62
observed a worse visual prognosis in cases of ischemic
ME compared to perfused ME. However, ﬁndings by
Finkelstein63 showed that 91% of 23 eyes with macular
ischemia recovered vision within one year with a VA of
20/40 or better. The conﬂicting reports and small num-
ber of studied eyes make it difﬁcult to reach deﬁnitive
conclusionsonvisualprognosisinpatientswithBRVO.
VA is a very sensitive indicator of the oxygen situa-
tion in the macula. For this reason, pre-treatment VA
may be an important prognostic factor. Six studies an-
alyzing the relation between initial and ﬁnal VA were
found.53,56,58,64−66 Five were used in an analysis of the
data of eyes with unsatisfactory ﬁnal VA (20/200 or
worse) in relation to initial VA (Table 2). There were 2
groups; the ﬁrst consisted of eyes with an initial VA of
20/50 or better and the second group of eyes with an
initial VA of 20/200 or worse. In the second group were
found a considerably higher percentage of eyes with a
ﬁnal VA of 20/200 or worse, regardless whether the eyes
had undergone laser treatment or not. Since there were
differently divided subgroups for ﬁnal VA, the study
of Subramanian et al.65 was not included in our anal-
ysis. Magargal et al.58 investigated the visual prognosis
in 246 eyes with BRVO divided into two groups: with
and without laser treatment. The obtained analysis il-
lustrates that in the group of eyes with an initial VA
20/50 or better, no eye (not receiving laser treatment)
and only 13% eyes (had undergone laser treatment) had
a ﬁnal VA of 20/200 or worse, whereas in the group of
TABLE 3 Final visual acuity 20/50 or better in relation to initial
visual acuity. Chi-squared test with Yates correction (p < 0.05)
Initial visual Initial visual
acuity 20/50 acuity 20/200 Chi-squared
or better or worse test p< 0.05
Natural course—without laser treatment
Gutman56 90% (18/20) 33% (4/12) Signiﬁcant
Magargal58 89% (31/35) 14% (4/29) Signiﬁcant
Had undergone laser treatment
Wetzig53 63% (5/8) 20% (3/15) No
Jalkh64 56% (5/9) 9% (1/12) Signiﬁcant
Magargal58 75% (30/40) 22% (14/64) Signiﬁcant
Lang66 77% (10/13) 13% (2/16) Signiﬁcant
eyes with an initial VA 20/200 or worse, 83% of eyes
(not receiving laser treatment) and 50% of eyes (had
undergone laser treatment) had this unsatisfactory ﬁ-
nal VA. In an analogous way, the data for the ﬁnal VA
20/50 or better in relation to the initial VA were ana-
lyzed(Table 3).Wecanseethatinthegroupofeyeswith
an initial VA 20/50 or better, 89% of eyes (not receiving
laser treatment), and 75% of eyes (had undergone laser
treatment) retained this good VA, whereas in the group
of eyes with an initial VA 20/200 or worse, only 14% of
eyes(notreceivinglasertreatment)andonly22%ofeyes
(hadundergonelasertreatment)hadaﬁnalVA20/50or
better.58 Similar data are reported in the other studies
(Tables 2 and 3). A chi-squared test with Yates correc-
tion was used to analyze the data. In 4 cases, in Table 2,
and in 5 cases, in Table 3, respectively, the results were
statistically signiﬁcant (p < 0.05). Our analysis shows
that in eyes with an initial VA 20/50 or better, the visual
prognosis is good even without treatment. It could also
be concluded that the cases of BRVO with an initial
VA of 20/200 or worse have a statistically signiﬁcantly
poorer visual prognosis than those with an initial VA
of 20/50 or better. Subramanian et al.65 showed that
in patients with BRVO who underwent laser treatment
of ME, the level of preoperative VA can be a useful
predictor of visual outcome.
TABLE 4 Treatment modalities for BRVO
1. Anti-aggregative therapy and ﬁrbrinolysis
2. Isovolemic hemodilution
3. Laser treatment
4. Intravitreal and periocular application of steroids
5. Intravitreal injection of VEGF inhibitors
6. Sheathotomy and vitrectomy
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Current treatment options focus on the sequelae of
the occluded venous branch, such as ME, retinal neo-
vascularization, vitreous hemorrhage, and traction reti-
naldetachment.Therehavebeenanumberoftreatment
modalities advocated for the management of BRVO
(Table 4). Many studies that examine interventions for
BRVO suffer from methodological limitations, includ-
inginsufﬁcientpowerresultingfromsmallsamplesizes,
short follow-up periods, absence of a control group
or inappropriate control group (absence of placebo or
best practice intervention as control groups), and lack
of distinction between clinical entities. A number of
such investigations have therefore produced conﬂict-
ing data. Hence, the results of randomized clinical tri-
als are the most important. The complex pathogenesis
of this disease requires investigation and treatment of
all risk factors (hypertension, diabetes mellitus, blood
lipid disorders, hematological disorders).
Anti-Aggregative Therapy and Fibrinolysis
Systemictreatmentwithoralacetylsalicylicacid,sub-
cutaneous heparin, or intravenous thrombolysis have
not been shown to be effective treatments for CRVO,
whileforBRVOnorandomizedclinicaltrialshavebeen
publishedasofthedateofthisreview.Thrombolysisus-
ing administration of tissue plasminogen activator in-
travitreally or directly into the retinal vein (mostly up-
per temporal branch close to the optic disc) has been
demonstrated to improve VA in patients with CRVO,67
but the results were based only on noncomparative in-
terventional series. There is no general current accep-
tance of this treatment.
Houtsmuller et al.,68 in a double-blind study, ex-
amined the platelet aggregation inhibiting effect of
ticlopidine in 54 patients with BRVO less than 3
weeks from the onset of symptoms. Compared with
placebo therapy a signiﬁcant improvement in VA was
observedwithticlopidinetherapyforsixmonths.Inthe
treated group, 69% of patients experienced an improve-
ment in VA, whereas 52% of placebo group reported
improvement.
Troxerutin has been suggested to inhibit erythrocyte
and platelet aggregation and to improve erythrocyte
deformability, thus reducing blood viscosity and the
retinal microcirculation.69 A double-blind randomized
study of 26 patients with BRVO compared troxerutin
with placebo.69 At 4 months follow-up, more of the pa-
tients receiving troxerutin treatment had a mean VA of
20/40 or better than the control group, although this
difference was not found to be statistically signiﬁcant.
After 4 months, all patients were treated with troxerutin
for 2 years. At the completion of this follow-up period
for those patients initially treated with troxerutin, a sig-
niﬁcant improvement in VA and improvement of ME
was demonstrated. The limitation of this study is that
there is no separation in the analysis of results for pa-
tients with BRVO and CRVO who were included in the
study, too.
Both studies mentioned that investigated the medi-
cal treatment of BRVO are limited by a small sample
size and short follow-up period (6 and 4 months).
Isovolaemic Hemodilution
Chen et al.20 demonstrated positive results for isov-
olemichemodilutiongivenupto3monthsaftertheon-
set of the symptoms of BRVO in patients with a hema-
tocrit of 35% or more. In this randomized controlled
study, 18 patients were treated for 6 weeks with vene-
section and volume replacement using hydroxyethyl-
starch and compared to 16 untreated control patients.
Afteraoneyearfollow-up,theﬁnalVAswere20/40and
20/80 for treated and untreated patients, respectively
(p = 0.03). Patients with ME and a VA 20/40 or worse
underwent3monthsafterincludingintothestudymac-
ular grid laser photocoagulation (MLG). Sector photo-
coagulationwasappliedifocularneovascularizationde-
veloped or if, at 3 months, the ﬂuorescein angiogram
showed an area of capillary non-perfusion greater than
5 disc areas. 28% of the hemodiluted patients required
MLG compared to 44% of the control group; this dif-
ference was not statistically signiﬁcant (p = 0.2). Sector
photocoagulation was required by 50% of both groups
of patients.20
Hydroxyethylstarch has a capacity to expand the
plasma volume by up to 172% of the volume in-
fused and has a duration of action of approximately
36 hours.70 It is non-antigenic and has a low incidence
of allergic reactions.71 Poupard et al.72 randomized 25
patientstoeitherhemodilutionwithdextranfor21days
(n = 10), hemodilution combined with heparin for
21 days (n = 10), or heparin treatment for 21 days fol-
lowedbyanti-vitaminKdrugsforafurther30days(n =
5). The study showed that, for those receiving heparin
followed by anti-vitamin K drugs, mean VA remained
unchanged to baseline values by 60 days. For those
treated with hemodilution and heparin, a statistically
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thosetreatedwithhemodilutionalone,asigniﬁcantim-
provementinVAwasfoundbyday14.Inarandomized
study by Hansen et al.73 of 35 patients with BRVO, 18
patients were treated by hemodilution for a period of
5 to 6 weeks (targeted hematocrit 30–35%). A control
group of 17 patients were only observed. At follow-up
12monthslater,25patientshadcompletedthetherapy.
Seven of the 13 who received hemodilution demon-
strated a VA increase of 2 lines or more compared with
none of the 12 patients who did not receive hemodi-
lution (p < 0.005). Reported complications of hemodi-
lution include headache, exertional dyspnea, tiredness,
deep vein thrombosis, and hypotension. The treatment
was noted to be generally well-tolerated even in elderly
patients.20,73,74
The use of hemodilution to treat BRVO is cur-
rently not generally accepted. Interpretation of the
above-mentioned studies is difﬁcult because most of
them incorporated other treatments in combination
with the hemodilution. Further prospective random-
ized trials with adequate controls and sufﬁcient follow-
up are required for any deﬁnitive conclusions and
recommendations.
Arteriovenous Crossing Sheathotomy
and Vitrectomy
Osterloh and Charles75 ﬁrst reported improvement
in VA in patients with BRVO after treatment using
the technique of surgical sheathotomy. The principle
steps of this procedure are a pars plana vitrectomy fol-
lowed by separation of the retinal artery from the vein
by creating an incision in the adventitial sheath adja-
cent to the A/V crossing and then separation of the
adhesions. Several studies have shown signiﬁcantly bet-
ter functional outcomes in patients treated by sheatho-
tomy compared to controls (Table 5).75−96 Reported
complications are few but include cataract, hemor-
rhage, retinal tears, postoperative gliosis, and retinal
detachment.75−96 Garcia-Arumi76 describedacombina-
tionofA/Vsheathotomyandinjectionofthrombolytic
into the occluded vein which resulted in thrombus re-
lease in 28% cases and signiﬁcant correlation with early
surgery and better ﬁnal VA. The role of the sheatho-
tomyaloneinvisualimprovementisinsufﬁcientlyclear.
Some authors suggest that vitrectomy is the most im-
portant part of the sheathotomy surgery, leading to re-
duction of ME.77,80,96 Yamamoto et al.77 compared the
effect of sheathotomy combined with vitrectomy to
the effect of vitrectomy alone and found no advantage
of sheathotomy. Eyes with pre-existing posterior vitre-
ous detachment were not studied. For this reason, the
beneﬁt of vitrectomy of these eyes is unknown. Sur-
gical detachment of posterior hyaloid could be more
important than the sheathotomy itself .78 The vitre-
ous is postulated to have a role in the pathogenesis
of neovascularization and ME, which may complicate
BRVO and its removal may help in the management
of these sight threatening complications.78 Vitrectomy
and removal of the posterior hyaloid with peeling of
the internal limiting membrane (ILM) appears to im-
prove oxygenation of the retina, which may lead to vi-
sual improvement.97,98 Peeling of the ILM improves
the surgical outcome during A/V adventitial sheatho-
tomy, too.84 To date, no randomized clinical trials on
the surgical treatment of BRVO have been published.
Any evidence supporting these procedures is based on
non-ramdomized case series only.
Steroids
Intravitreal Corticosteroids
In several nonrandomized comparative studies, in-
travitreal corticosteroids were successfully used for the
treatment of BRVO. Currently published randomized
studies are very rare and limited by virtue of evaluating
patients with ME of different etiology, making com-
parisons difﬁcult. In various studied doses from 4 to
25 mg, triamcinolone acetonide (TA) has been reported
to be effective99−117 (Table 6). In a randomized, inter-
ventional, three-arm clinical trial, Avitable et al.99 com-
paredtheresultsoftreatingdiabeticpatientsandasmall
group of BVRO patients with cystoid ME by TA and
MLG. From a total of 63 patients, 22 were treated by
TA(4mg),21underwentMLG,andin20patientsthese
methods were combined (TA + MLG). The greatest im-
provement in VA was found in patients treated by TA
combined with MLG. VA (log MAR) in this group in-
creased signiﬁcantly from 0.83 at baseline to 0.20 at the
end of follow-up 9 months later (p = 0.003). In patients
treated by TA, VA improved signiﬁcantly, from 0.82 at
baseline to 0.23 at 9 months after injection (p = 0.04).
VA in the group of patients treated by MLG remained
the same. The results of this study are limited, however,
owing to the different ME etiologies in evaluated pa-
tients; only 6 patients had ME secondary to BRVO. Oh
et al.100 used a retrospective interventional case series
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e
g
r
o
u
p
s
(
p
=
0
.
5
;
p
=
0
.
6
r
e
s
p
e
c
t
i
v
e
l
y
)
.
M
a
r
t
i
n
e
z
-
S
o
r
o
a
e
t
a
l
.
9
1
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
1
7
e
y
e
s
—
s
h
e
a
t
h
o
t
o
m
y
.
6
m
o
n
t
h
s
.
I
m
p
r
o
v
e
m
e
n
t
i
n
V
A
f
r
o
m
0
.
2
6
t
o
0
.
4
.
5
3
%
p
a
t
i
e
n
t
s
i
m
p
r
o
v
e
d
≥
4
l
i
n
e
s
(
S
n
e
l
l
e
n
)
.
L
e
R
o
u
i
c
9
2
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
3
e
y
e
s
—
s
h
e
a
t
h
o
t
o
m
y
.
1
0
m
o
n
t
h
s
.
N
o
i
m
p
r
o
v
e
m
e
n
t
i
n
V
A
o
b
s
e
r
v
e
d
.
A
l
l
p
a
t
i
e
n
t
s
w
i
t
h
i
n
i
t
i
a
l
V
A
<
2
0
/
4
0
.
D
o
t
r
e
l
o
v
a
e
t
a
l
.
9
3
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
3
e
y
e
s
—
s
h
e
a
t
h
o
t
o
m
y
.
1
2
m
o
n
t
h
s
.
V
A
i
m
p
r
o
v
e
d
i
n
2
p
a
t
i
e
n
t
s
t
o
2
0
/
4
0
,
i
n
1
p
a
t
i
e
n
t
s
t
a
b
i
l
i
z
e
d
(
2
0
/
1
8
0
)
.
S
h
a
h
e
t
a
l
.
9
4
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
5
e
y
e
s
—
s
h
e
a
t
h
o
t
o
m
y
.
6
.
5
y
e
a
r
s
.
V
A
p
r
e
o
p
e
r
a
t
i
v
e
i
n
a
l
l
p
a
t
i
e
n
t
s
≤
2
0
/
2
0
0
.
I
m
p
r
o
v
e
d
i
n
4
e
y
e
s
f
r
o
m
2
0
/
3
0
t
o
2
0
/
7
0
.
1
e
y
e
w
i
t
h
c
o
u
n
t
i
n
g
ﬁ
n
g
e
r
s
r
e
m
a
i
n
e
d
u
n
c
h
a
n
g
e
d
.
C
r
a
f
o
o
r
d
e
t
a
l
.
9
5
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
1
2
e
y
e
s
—
s
h
e
a
t
h
o
t
o
m
y
.
2
0
m
o
n
t
h
s
.
V
A
i
m
p
r
o
v
e
d
i
n
9
e
y
e
s
(
7
5
%
)
,
i
n
1
e
y
e
(
8
.
3
%
)
r
e
m
a
i
n
e
d
u
n
c
h
a
n
g
e
d
a
n
d
d
e
t
e
r
i
o
r
e
d
i
n
2
e
y
e
s
(
1
6
.
7
%
)
.
2
p
a
t
i
e
n
t
s
r
e
c
e
i
v
e
d
a
d
d
i
t
i
o
n
a
l
l
y
2
5
m
g
t
r
i
a
m
c
i
n
o
l
o
n
e
a
c
e
t
o
n
i
d
e
a
t
t
h
e
e
n
d
o
f
t
h
e
s
u
r
g
e
r
y
.
H
a
n
e
t
a
l
.
9
6
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
a
s
e
s
e
r
i
e
s
.
2
0
e
y
e
s
—
p
a
r
s
p
l
a
n
a
v
i
t
r
e
c
t
o
m
y
a
n
d
d
i
s
s
e
c
t
i
o
n
o
f
t
h
e
a
r
t
e
r
i
o
v
e
n
o
u
s
c
r
o
s
s
i
n
g
w
i
t
h
o
u
t
s
e
p
a
r
a
t
i
o
n
o
f
t
h
e
v
e
s
s
e
l
s
.
1
0
.
5
m
o
n
t
h
s
.
I
n
1
6
e
y
e
s
(
8
0
%
)
i
m
p
r
o
v
e
d
V
A
≥
2
l
i
n
e
s
.
M
e
a
n
i
m
p
r
o
v
e
m
e
n
t
o
f
V
A
(
l
o
g
M
A
R
)
w
a
s
=
0
.
4
4
±
0
.
1
4
(
p
=
0
.
0
1
6
)
.
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A
B
L
E
6
S
u
m
m
a
r
y
o
f
s
t
u
d
i
e
s
e
v
a
l
u
a
t
i
n
g
t
h
e
t
r
e
a
t
m
e
n
t
o
f
m
a
c
u
l
a
r
e
d
e
m
a
i
n
B
R
V
O
b
y
i
n
t
r
a
v
i
t
r
e
a
l
a
p
p
l
i
c
a
t
i
o
n
o
f
t
r
i
a
m
c
i
n
o
l
o
n
e
a
c
e
t
o
n
i
d
e
(
T
A
=
t
r
i
a
m
c
i
n
o
l
o
n
e
a
c
e
t
o
n
i
d
e
,
V
A
=
v
i
s
u
a
l
a
c
u
i
t
y
,
M
E
=
m
a
c
u
l
a
r
e
d
e
m
a
,
M
L
G
=
m
a
c
u
l
a
r
l
a
s
e
r
g
r
i
d
p
h
o
t
o
c
o
a
g
u
l
a
t
i
o
n
)
A
u
t
h
o
r
S
t
u
d
y
t
y
p
e
P
a
t
i
e
n
t
s
F
o
l
l
o
w
-
u
p
(
m
e
a
n
)
O
u
t
c
o
m
e
s
C
o
m
m
e
n
t
s
A
v
i
t
a
b
i
l
e
e
t
a
l
.
9
9
R
a
n
d
o
m
i
z
e
d
i
n
t
e
r
v
e
n
t
i
o
n
a
l
,
p
a
r
a
l
l
e
l
,
t
h
r
e
e
-
a
r
m
c
l
i
n
i
c
a
l
t
r
i
a
l
.
I
n
t
r
a
v
i
t
r
e
a
l
T
A
(
4
m
g
)
:
2
2
e
y
e
s
.
M
L
G
:
2
1
e
y
e
s
.
T
A
+
M
L
G
:
2
0
e
y
e
s
.
9
m
o
n
t
h
s
.
T
A
g
r
o
u
p
:
V
A
i
m
p
r
o
v
e
d
f
r
o
m
0
.
8
2
t
o
0
.
2
3
l
o
g
M
A
R
(
p
=
0
.
0
4
)
.
M
L
G
-
g
r
o
u
p
:
V
A
u
n
c
h
a
n
g
e
d
.
T
A
+
M
L
G
g
r
o
u
p
,
V
A
i
m
p
r
o
v
e
d
f
r
o
m
0
.
8
3
t
o
0
.
2
0
.
l
o
g
M
A
R
(
p
=
0
.
0
0
3
)
.
D
i
f
f
e
r
e
n
t
e
t
i
o
l
o
g
y
o
f
M
E
,
o
n
l
y
6
e
y
e
s
w
i
t
h
B
R
V
O
.
O
h
e
t
a
l
.
1
0
0
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
o
m
p
a
r
a
t
i
v
e
c
a
s
e
s
e
r
i
e
s
.
2
0
e
y
e
s
w
i
t
h
M
E
(
4
m
g
T
A
)
D
i
s
e
a
s
e
d
u
r
a
t
i
o
n
:
1
0
e
y
e
s
≤
3
m
o
n
t
h
s
;
1
0
e
y
e
s
>
3
m
o
n
t
h
s
.
6
m
o
n
t
h
s
.
G
r
o
u
p
≤
3
m
o
n
t
h
s
:
V
A
(
l
o
g
M
A
R
)
i
m
p
r
o
v
e
d
f
r
o
m
1
.
0
7
t
o
0
.
6
3
i
n
1
m
o
n
t
h
(
p
=
0
.
0
1
2
)
a
n
d
t
o
0
.
3
4
i
n
6
m
o
n
t
h
s
(
p
=
0
.
0
0
5
)
.
G
r
o
u
p
>
3
m
o
n
t
h
s
:
V
A
i
m
p
r
o
v
e
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
o
n
l
y
i
n
1
m
o
n
t
h
f
r
o
m
0
.
8
0
t
o
0
.
4
7
(
p
=
0
.
0
3
9
)
.
V
A
i
n
6
m
o
n
t
h
s
l
o
s
t
s
i
g
n
i
ﬁ
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
(
0
.
6
;
p
=
0
.
2
2
6
)
.
O
z
k
i
r
i
s
e
t
a
l
.
1
0
1
R
e
t
r
o
s
p
e
c
t
i
v
e
,
n
o
n
-
c
o
n
t
r
o
l
l
e
d
c
a
s
e
s
e
r
i
e
s
.
1
9
t
r
e
a
t
e
d
e
y
e
s
(
8
m
g
T
A
)
.
6
.
2
m
o
n
t
h
s
.
V
A
(
l
o
g
M
A
R
)
i
m
p
r
o
v
e
d
f
r
o
m
1
.
0
1
±
0
.
1
6
t
o
0
.
6
2
±
0
.
2
2
.
V
A
i
m
p
r
o
v
e
d
i
n
1
7
e
y
e
s
a
n
d
r
e
m
a
i
n
e
d
u
n
c
h
a
n
g
e
d
i
n
2
e
y
e
s
.
J
o
n
a
s
e
t
a
l
.
1
0
2
P
r
o
s
p
e
c
t
i
v
e
n
o
n
r
a
n
d
o
m
i
z
e
d
c
o
m
p
a
r
a
t
i
v
e
s
t
u
d
y
.
1
0
t
r
e
a
t
e
d
e
y
e
s
(
2
0
m
g
T
A
)
.
2
0
u
n
t
r
e
a
t
e
d
c
o
n
t
r
o
l
s
.
T
A
p
a
t
i
e
n
t
s
:
1
0
.
1
m
o
n
t
h
s
.
C
o
n
t
r
o
l
s
:
6
m
o
n
t
h
s
.
T
A
p
a
t
i
e
n
t
s
:
V
A
i
n
c
r
e
a
s
e
d
f
r
o
m
0
.
2
7
±
0
.
1
1
t
o
0
.
4
5
±
0
.
2
7
(
p
=
0
.
0
2
)
.
C
o
n
t
r
o
l
s
:
V
A
d
e
c
r
e
a
s
e
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
(
p
=
0
.
0
0
7
)
.
V
A
i
n
c
r
e
a
s
e
d
h
i
g
h
e
r
i
n
n
o
n
-
i
s
c
h
e
m
i
c
g
r
o
u
p
.
S
i
g
n
i
ﬁ
c
a
n
t
i
n
c
r
e
a
s
e
o
f
i
n
t
r
a
o
c
u
l
a
r
p
r
e
s
s
u
r
e
i
n
t
r
e
a
t
e
d
g
r
o
u
p
.
C
e
k
i
c
e
t
a
l
.
1
0
3
R
e
t
r
o
s
p
e
c
t
i
v
e
n
o
n
-
c
o
n
t
r
o
l
l
e
d
c
a
s
e
s
e
r
i
e
s
.
1
3
e
y
e
s
(
4
m
g
T
A
)
.
1
3
m
o
n
t
h
s
.
V
A
:
i
m
p
r
o
v
e
d
i
n
7
e
y
e
s
,
r
e
m
a
i
n
e
d
t
h
e
s
a
m
e
i
n
4
e
y
e
s
,
w
o
r
s
e
n
e
d
i
n
2
e
y
e
s
.
F
o
v
e
o
l
a
r
t
h
i
c
k
n
e
s
s
d
e
c
r
e
a
s
e
d
i
n
5
6
%
o
f
p
a
t
i
e
n
t
s
(
p
<
0
.
0
0
1
)
.
V
A
i
m
p
r
o
v
e
m
e
n
t
s
i
g
n
i
ﬁ
c
a
n
t
l
y
c
o
r
r
e
l
a
t
e
d
w
i
t
h
p
a
t
i
e
n
t
a
g
e
(
p
=
0
.
0
2
6
)
.
(
C
o
n
t
i
n
u
e
d
o
n
n
e
x
t
p
a
g
e
)
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6
S
u
m
m
a
r
y
o
f
s
t
u
d
i
e
s
e
v
a
l
u
a
t
i
n
g
t
h
e
t
r
e
a
t
m
e
n
t
o
f
m
a
c
u
l
a
r
e
d
e
m
a
i
n
B
R
V
O
b
y
i
n
t
r
a
v
i
t
r
e
a
l
a
p
p
l
i
c
a
t
i
o
n
o
f
t
r
i
a
m
c
i
n
o
l
o
n
e
a
c
e
t
o
n
i
d
e
(
T
A
=
t
r
i
a
m
c
i
n
o
l
o
n
e
a
c
e
t
o
n
i
d
e
,
V
A
=
v
i
s
u
a
l
a
c
u
i
t
y
,
M
E
=
m
a
c
u
l
a
r
e
d
e
m
a
,
M
L
G
=
m
a
c
u
l
a
r
l
a
s
e
r
g
r
i
d
p
h
o
t
o
c
o
a
g
u
l
a
t
i
o
n
)
(
C
o
n
t
i
n
u
e
d
)
A
u
t
h
o
r
S
t
u
d
y
t
y
p
e
P
a
t
i
e
n
t
s
F
o
l
l
o
w
-
u
p
(
m
e
a
n
)
O
u
t
c
o
m
e
s
C
o
m
m
e
n
t
s
L
e
e
e
t
a
l
.
1
0
4
R
e
t
r
o
s
p
e
c
t
i
v
e
,
n
o
n
-
c
o
n
t
r
o
l
l
e
d
c
a
s
e
s
e
r
i
e
s
.
6
e
y
e
s
(
4
m
g
T
A
)
.
1
4
9
.
5
d
a
y
s
.
I
m
p
r
o
v
e
m
e
n
t
i
n
V
A
≥
2
l
i
n
e
s
i
n
5
e
y
e
s
(
8
3
.
3
%
)
.
V
A
f
r
o
m
2
0
/
1
6
6
t
o
ﬁ
n
a
l
2
0
/
1
0
6
.
3
e
y
e
s
t
r
e
a
t
e
d
w
i
t
h
r
e
-
a
p
p
l
i
c
a
t
i
o
n
o
f
T
A
.
O
z
k
i
r
i
s
e
t
a
l
.
1
0
5
R
e
t
r
o
s
p
e
c
t
i
v
e
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
o
m
p
a
r
a
t
i
v
e
c
a
s
e
s
e
r
i
e
s
.
1
5
e
y
e
s
(
8
m
g
T
A
)
.
1
9
e
y
e
s
M
L
G
.
6
.
3
m
o
n
t
h
s
.
V
A
(
l
o
g
M
A
R
)
i
m
p
r
o
v
e
d
i
n
T
A
g
r
o
u
p
f
r
o
m
0
.
9
8
t
o
0
.
2
4
a
n
d
i
n
M
L
G
g
r
o
u
p
f
r
o
m
1
.
0
2
t
o
0
.
5
(
i
n
b
o
t
h
g
r
o
u
p
s
p
<
0
.
0
0
1
)
.
I
m
p
r
o
v
e
m
e
n
t
i
n
T
A
g
r
o
u
p
w
a
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
h
i
g
h
e
r
t
h
a
n
i
n
M
L
G
(
p
<
0
.
0
0
1
)
.
Y
e
p
r
e
m
y
a
n
e
t
a
l
.
1
0
6
R
e
t
r
o
s
p
e
c
t
i
v
e
,
n
o
n
-
c
o
n
t
r
o
l
l
e
d
c
a
s
e
s
e
r
i
e
s
.
1
2
e
y
e
s
(
4
m
g
T
A
)
.
1
5
.
3
m
o
n
t
h
s
.
V
A
i
m
p
r
o
v
e
d
>
3
l
i
n
e
s
i
n
5
0
%
o
f
e
y
e
s
a
f
t
e
r
1
m
o
n
t
h
a
n
d
i
n
4
2
%
o
f
e
y
e
s
a
t
l
a
s
t
f
o
l
l
o
w
u
p
.
8
e
y
e
s
d
e
v
e
l
o
p
e
d
r
e
c
u
r
r
e
n
t
M
E
a
t
a
n
a
v
e
r
a
g
e
o
f
5
.
5
m
o
n
t
h
s
a
f
t
e
r
i
n
i
t
i
a
l
T
A
i
n
j
e
c
t
i
o
n
.
C
h
e
n
g
e
t
a
l
.
1
0
7
P
r
o
s
p
e
c
t
i
v
e
n
o
n
r
a
n
d
o
m
i
z
e
d
i
n
t
e
r
v
e
n
t
i
o
n
a
l
c
o
m
p
a
r
a
t
i
v
e
s
t
u
d
y
.
1
6
e
y
e
s
(
4
m
g
T
A
)
.
1
1
c
o
n
t
r
o
l
s
(
w
i
t
h
o
u
t
T
A
)
.
1
0
3
d
a
y
s
i
n
T
A
-
g
r
o
u
p
.
9
4
.
5
d
a
y
s
i
n
c
o
n
t
r
o
l
s
.
V
A
(
l
o
g
M
A
R
)
.
I
n
T
A
-
g
r
o
u
p
:
i
m
p
r
o
v
e
m
e
n
t
f
r
o
m
0
.
7
7
±
0
.
4
3
t
o
0
.
4
4
±
0
.
4
3
(
p
<
0
.
0
0
1
)
.
N
o
s
i
g
n
i
ﬁ
c
a
n
t
c
h
a
n
g
e
o
f
V
A
i
n
c
o
n
t
r
o
l
s
.
S
i
g
n
i
ﬁ
c
a
n
t
r
e
d
u
c
t
i
o
n
o
f
M
E
i
n
T
A
-
g
r
o
u
p
(
P
<
0
.
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124to compare VA after single TA injection (4 mg) in 10 pa-
tientswithmeandurationofME≤3monthsafteronset
of BRVO versus 10 patients with ME > 3 months after
onset. In patients with a disease duration ≤3 months,
VA signiﬁcantly improved from baseline over 6 months
of follow-up. However in those with a duration of >3
months, improved VA, though apparent at one month,
was not maintained at 3 or 6 months after TA injection.
Thisstudyislimitedbyitsretrospectivedesignandshort
follow-up period. Ozkiris et al.101 evaluated the effect
of TA injection on persistent ME in BRVO that failed
to respond to previous laser photocoagulation. During
a mean follow-up time of 6.2 months, best corrected
VA (log MAR) improved signiﬁcantly (p < 0.001) from
1.01atbaselineto0.55atonemonthaftertheinjection.
VA after 3 months was 0.56, and at the end of follow-up
was 0.62. The authors concluded that intravitreal appli-
cation of TA may be helpful in patients who do not
respond to laser photocoagulation. However, in pub-
lished studies, the resulting reduced macular thickness
and improved VA, is only temporary and requires re-
peated treatment. One to four times re-application has
been reported. Cekic et al.103 performed a retrospective
chart review of 13 patients who underwent intravitreal
injections with 4 mg TA. Six eyes received a single in-
jection. Repeated injections were performed in 1 eye
twice, 4 eyes three times, and 2 eyes four times. During
a mean follow-up of 13 months, central foveal thick-
ness decreased by more than 50%. Final VA improved
in 7 eyes (range 2–6 Snellen lines), remained the same
in 4 eyes (range 0–1 Snellen lines), and worsened in
2 eyes (range 1–4 Snellen lines) compared to baseline.
Retinal thickness decreased in all cases, while vision im-
proved in most cases. One of the most common side
effects of TA was steroid-induced elevation of intraocu-
lar pressure.118 Other complications were infectious en-
dophthalmitis, post-injection steroid-induced cataract,
and retinal detachment.119,120 Reported risk of infec-
tious endophthalmitis per injection range was from
0.1% to 1.6%.120 The most recent report by Bhavsar
etal.121 foundintwolargestudies-DiabeticRetinopathy
Clinical Research Network (DRCR.net) and SCORE
(Standard Care versus Corticosteroid for Retinal Vein
Occlusion), an endophthalmitis prevalence of 0.05%
(one case in the 2009 injections).
MostpublishedstudiesonintravitrealTAforBRVO,
however, suffer from two serious ﬂaws: either the de-
signs are not randomized or they often do not clearly
differentiate between nonischemic types and ischemic
types of occlusion. To compare the effectiveness and
safety of standard care versus TA injection in the
treatment of ME in patients with CRVO and BRVO,
the multicenter randomized study SCORE is ongoing
(https://web.emmes.com/study/score). In each of the
two disease areas, 630 participants will be randomized
in a 1:1:1 ratio to one of three groups: standard care,
intravitreal 4 mg of TA, or 1 mg of TA. The follow-up
is planned for 3 years. The results are not published
as yet. Biodegradable intravitreal implants may allow
steroid delivery over a more sustained period, permit-
ting longer duration of action. A multicenter random-
ized clinical trial which evaluates implantation of dex-
amethasone 350 μgo r7 0 0μg (Posurdex) versus obser-
vation(notherapy)forMEsecondarytoavarietyofreti-
nal disorders (including BRVO) has been reported.117
The preliminary 90-day results of all 315 evaluated pa-
tients showed that an improvement in VA of 10 letters
or more (in ETDRS) was achieved by a greater pro-
portion of patients treated with dexamethasone 700 μg
(35%) or 350 μg (24%), than untreated patients (13%;
p < 0.001 versus 700 μg group; p = 0.04 versus 350
μg group). The results were similar for patients with di-
abetic retinopathy, retinal vein occlusion, or uveitis or
Irvine-Gass syndrome. In total, 60 patients with BRVO
were randomized 1:1:1 to receive 350 μgo r7 0 0μg
dexamethasone or observation (no therapy). In the case
of RVO, the effect of the treatment was evaluated only
in a common group (CRVO and BRVO patients to-
gether): an improvement in VA of 10 letters or more
was achieved in 15% of untreated patients versus 31%
of patients treated with dexamethasone 700 μg. The
number of patients with an increase in intraocular pres-
sure of more than 10 mmHg from baseline anytime
during the study was 12% for 350 μg, 17% for 700 μg,
and 3% for the untreated controls.117
Periocular Application of Triamcinolone
Acetonide
Kawaji et al.122 evaluated in 20 patients the effective-
ness and safety of trans-tenon retrobulbar injection of
40 mg of TA for ME associated with BRVO after vitrec-
tomy. Improvement in VA was seen in 14 (70%) eyes.
Hayashi et al.123 compared in a randomized clinical
trial, the short-term effect of intravitreal versus retrob-
ulbar injection of TA for the treatment of ME caused
by BRVO. Sixty patients received either a single in-
travitreal injection (4 mg) or repeated retrobulbar in-
jections (40 mg, three times) of TA. The ﬁrst injection
125 Pathogenesis and Treatment Modalities in BRVOin the retrobulbar group was given approximately one
week after focal laser photocoagulation. Foveal thick-
ness,macularvolume,andimprovementinVAweresig-
niﬁcantly better after intravitreal injection than after re-
peatedretrobulbarinjections.Theneedforre-injections
was signiﬁcantly greater in the retrobulbar group than
in the intravitreal group.
Intravitreal Injection of VEGF Inhibitors
VEGF inhibitors are a treatment option for ME as-
sociated with RVO that target the disease at the causal
molecular level. Randomized studies evaluating the re-
sults of treatment of all available VEGF inhibitors (be-
vacizumab, ranibizumab, and pegaptanib) are ongoing.
Case reports, small retrospective or prospective non-
controlled studies of VEGF inhibitors in the treatment
of ME and retinal neovascularizations secondary to
BRVO, have been published.124−140
Rosenfeldetal.124 ﬁrstreportedimprovedVAandre-
duced ME measured by optical coherent tomography
(OCT) following intravitreal injection of bevacizumab
for recurrent ME secondary to CRVO in an eye pre-
viously treated by intravitreal TA injection. In a short-
term study, Iturralde et al.125 treated 16 eyes of CRVO
with ME that had failed intravitreal corticosteroid ther-
apy, and nearly every eye showed some anatomic or
VA improvement following bevacizumab injection. In
variousreports,dosesfrom1.25to2.5mgbevacizumab
have been intravitreally administrated.125−134 The most
recently published studies evaluated the results in a
group of patients with BRVO combined with patients
with CRVO. In all of these studies, bevacizumab in-
jection improved VA and reduced macular thickness
measured by OCT within the ﬁrst 3 to 9 weeks. Few
studies are available for BRVO patients alone.126,127
Rabena et al.126 reported a signiﬁcantly increased VA
andreducedmacularthicknessaftertreatmentwith1.25
mg bevacizumab in a retrospective study of 27 patients
with BRVO. Recurrent ME was observed in 6 (22%)
patients an average of 2.1 months after the initial in-
jection. These patients were reinjected and all showed
moderate to complete reduction in ME. The limita-
tions of this retrospective study are short follow-up and
lack of control group. Additionally, most of the eyes
in the study were previously treated and thus failed
standard treatment, and perhaps represent a group un-
likely to beneﬁt from any treatment. All published re-
ports provide evidence that this treatment is well tol-
erated. The most common adverse events were con-
junctival hyperemia and subconjunctival hemorrhage
at the injection site. However, the duration of reduced
ME after bevacizumab administration is currently un-
known. Frequent repeated injections are required to
prevent a rebound effect with no clearly deﬁned
endpoint.128
Campochiaro et al.129 presented preliminary results
of a randomized study in the treatment of BRVO with
intravitrealinjectionofranibizumabatthe2007Annual
MeetingofAssociationonResearchandVisioninOph-
thalmology (ARVO). Patients with ME due to CRVO
or BRVO were randomized 1:1 to receive 3 monthly
injections of 0.5 or 0.3 mg of ranibizumab. Interim re-
sults without regard to treatment assignment, which is
unknown, showed that 12 randomized patients with
BRVO gained an improvement in VA (in ETDRS) from
21 to 37 letters and a reduction in ME from 508 to 208
μm after 3 months of treatment. The endpoint results
areexpectedtoclarifyanydifferencesbetweenthetreat-
ment groups. Another indication for anti-VEGF drugs
are retinal neovascularizations, rubeosis iridis, and neo-
vascular glaucoma. Rapid regression of neovasculariza-
tions and compensation of intraocular pressure have
been described in several studies.136−139 Intracameral
application of bevacizumab as successful treatment of
rubeosis iridis and neovascular glaucoma has also been
reported.140
Prospective, controlled studies are mandatory to de-
velop standardized treatment protocols that allow safe
and effective application of anti-VEGF drugs.
Laser Treatment
Laser treatment is an established method for use in
patients with BRVO. A large number of publications
concerning the role of photocoagulation in the man-
agement of BRVO have appeared. Various laser tech-
niques can be used: macula grid photocoagulation and
the method of arterial crimping for treatment of ME,
and peripheral scatter photocoagulation for treatment
of retinal and/or disc neovascularization.
Macular Grid Laser Photocoagulation
The Branch vein occlusion study group remains the
largest randomized prospective trial that has evaluated
the efﬁcacy of grid-pattern laser photocoagulation for
the treatment of ME in BRVO.141 In this study, only
eyes with recent BRVO, perfused ME, resolved foveal
hemorrhage, VA 20/40 or worse, and no other ocular
comorbidities were included. After a 3-year follow-up
J. Rehak and M. Rehak 126period, 65% of treated eyes gained improvement of 2
or more lines from baseline, as opposed to 37% of un-
treated eyes. The number of eyes that lost 2 or more
lineswasnotsigniﬁcantlydifferentinthetwogroups.141
Parodietal.publishedtworandomizedcontrolledstud-
ies, in which no signiﬁcant beneﬁt of MLG on VA
was found.142,143 MLG is recommended as an effective
treatmenttoreducetheMEinBRVOafteraperiodof3
to 6 months after onset and following absorption of the
majority of hemorrhage if VA is 20/40 or worse.61,62,141
If the ﬂuorescein angiogram reveals macular nonper-
fusion, laser therapy is not warranted.141 Subramanian
et al.65 recommended laser treatment in patients with
poor VA (20/200 or worse) secondary to ME due to
BRVO, before more aggressive approaches (as intravit-
real TA). Argon MLG is usually used for this purpose.
However, diode laser (810 nm) and krypton red laser
(647 nm) also can be used.63,141,144
Scatter Photocoagulation
The randomized controlled study by Branch vein oc-
clusion study group54 reported that peripheral scatter
laser photocoagulation signiﬁcantly reduced the devel-
opmentofretinalneovascularizationandvitreoushem-
orrhage. This study also demonstrated that, if all eyes
with large retinal nonperfusion were treated, 64% of
these patients would never develop neovascularization.
If only the eyes that develop neovascularization were
treated, the events of vitreous hemorrhage would de-
crease from 61% to 29%. Since loss in the lower part
of the visual ﬁeld can produce marked disability and
BRVO involving the superior retina is common, a sig-
niﬁcant worsening of visual ﬁelds with laser treatment
becomesaveryimportant,clinicallyrelevantﬁnding.145
Therefore, waiting is generally advocated until neovas-
cularization actually develops before scatter photoco-
agulation is considered.54
Arteriolar Constriction
An alternative type of laser treatment involves arteri-
olar constriction (called also “crimping technique”) and
may be considered in order to reduce the inﬂow into
the affected area if the ME is excessive. This procedure
was ﬁrst described by L’Esperance146 in 1975. It may
lead to a decrease in arterial pressure in the occluded
region resulting in better drainage of the ME due to
reduced blood inﬂow. The technique is employed by
placing coagulations at approximate intervals of 1/ 2 disc
diameter (using the green beam of argon laser) through
the afferent arteriole in the region of venous blockage.
In 1984 Jalkh et al.64 proposed their own modiﬁcation
of this method and published the results obtained in 41
eyes. In this study, arterial constriction was applied in
the treatment of the chronic stage of BRVO. Rehak et
al. published several studies describing the modiﬁed ar-
teriolarconstrictioninpatientswithBRVO.147−149 This
techniqueconsistsoftheapplicationofcoalescentcoag-
ulationspotsthroughtheafferentarteriolethatsupports
the occluded venous region. 83% of patients treated by
this method within the ﬁrst 2 months after the onset of
occlusion achieved a ﬁnal VA 20/40 or better.149 In a
study by Erdol and Akyol,150 the improvement in VA
was higher in a group of patients receiving the MLG
combined with arteriolar constriction than in a group
treated by MLG only. However, the difference in the
resolution of ME between the groups was not statis-
tically signiﬁcant. The authors suggest that arteriolar
constriction in addition to grid pattern laser photoco-
agulation is more effective for resolving ME in patients
with BRVO.
CONCLUSIONS
The pathogenesis of BRVO is multifactorial. Its re-
sulting visual loss is due primarily to ME, macular
nonperfusion, and retinal neovascularization. A large
number of treatments have been advocated in its man-
agement. Unfortunately, almost all of these lack suf-
ﬁcient evidence for their effectiveness. Randomized
prospective trials are essential. The only one established
treatment for ME is macular grid photocoagulation in
patients with BRVO longer than 3 months and a VA of
20/40 or worse. Additionally, the initial VA may play a
crucial role in the prognosis of BRVO and determinates
the ﬁnal VA.
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